세계의 패혈증 진단 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 기술별, 제품 유형별, 진단 방법별, 병원체별, 지역별, 경쟁별(2020-2030년)
Sepsis Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Product, By Diagnostic Method, By Pathogen, By Region and Competition, 2020-2030F
세계의 패혈증 진단 시장은 2024년에는 6억 1,225만 달러로 평가되었고, 2030년에는 9억 5,418만 달러에 이를 것으로 예측되며, 예측 기간 동안 CAGR은 7.68%를 나타낼 전망입니다.
패혈증은 감염에 대한 불균형한 면역 반응으로 인해 전신 염증과 잠재적인 장기 부전으로 이어지는 생명을 위협하는 심각한 질환입니다. 환자의 생존율을 높이고 합병증을 예방하기 위해서는 신속한 진단과 치료가 필수적입니다. 전 세계적으로 패혈증 발병률이 증가하고 의료 전문가와 대중의 인식이 높아짐에 따라 신속하고 정확한 진단 솔루션에 대한 수요가 증가하고 있습니다. 패혈증 진단은 분자 기술, 면역 분석, 자동화된 혈액 배양 시스템의 발전으로 크게 발전했습니다. 이러한 기술을 통해 패혈증을 조기에 발견하고 병원체를 식별하여 적시에 치료할 수 있게 되었습니다. 고령화 인구의 감염에 대한 취약성 증가와 병원 입원 증가는 시장 성장에 더욱 기여하고 있습니다. 의료 시스템이 패혈증 조기 관리에 우선순위를 두면서 혁신과 지속적인 R&D 노력에 힘입어 효율적인 진단 도구에 대한 수요는 계속 증가하고 있습니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모(2024년) |
6억 1,225만 달러 |
| 시장 규모(2030년) |
9억 5,418만 달러 |
| CAGR(2025-2030년) |
7.68% |
| 급성장 부문 |
분자 진단 |
| 최대 시장 |
북미 |
시장 성장 촉진요인
패혈증 진단 기술의 발전
주요 시장 과제
제네릭 의약품 경쟁
주요 시장 동향
바이오마커 발견
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 목소리
제5장 세계의 패혈증 진단 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 기술별(분자 진단, 미생물학, 면역 측정, 기타 기술)
- 제품 유형별(기기, 분석 및 시약, 기타 제품)
- 진단 방법별(기존 진단, 자동 진단)
- 병원체별(세균성 패혈증, 진균성 패혈증, 기타 병원체)
- 지역별
- 기업별(2024년)
- 시장 맵
제6장 북미의 패혈증 진단 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 북미 : 국가별 분석
제7장 유럽의 패혈증 진단 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 패혈증 진단 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 아시아태평양 : 국가별 분석
제9장 남미의 패혈증 진단 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 패혈증 진단 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 중동 및 아프리카 : 국가별 분석
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
제11장 시장 역학
제12장 시장 동향과 발전
제13장 세계의 패혈증 진단 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
- 업계 내 경쟁
- 신규 진입의 가능성
- 공급자의 힘
- 고객의 힘
- 대체 치료법의 위협
제15장 경쟁 구도
- Abbott Laboratories Inc.
- DiaSorin SpA
- Becton, Dickinson and Company
- BioMerieux Inc.
- F. Hoffmann-La Roche AG
- Danaher Corporation
- Thermo Fisher Scientific Inc
- Siemens Healthineers AG
- Seegene, Inc.
- Roche Diagnostics Corporation
제16장 전략적 제안
제17장 기업 소개와 면책사항
HBR
The Global Sepsis Diagnostics Market was valued at USD 612.25 Million in 2024 and is projected to reach USD 954.18 Million by 2030, growing at a CAGR of 7.68% during the forecast period. Sepsis is a critical, life-threatening condition resulting from an imbalanced immune response to infection, leading to systemic inflammation and potential organ failure. Prompt diagnosis and treatment are essential to improve patient survival and prevent complications. The growing incidence of sepsis globally, coupled with heightened awareness among healthcare professionals and the public, is driving the demand for rapid and accurate diagnostic solutions. Sepsis diagnostics have evolved significantly with advancements in molecular techniques, immunoassays, and automated blood culture systems. These technologies allow earlier detection and pathogen identification, enabling timely therapeutic interventions. The increasing susceptibility of the aging population to infections, along with rising hospital admissions, further contributes to market growth. As healthcare systems prioritize early sepsis management, the demand for efficient diagnostic tools continues to grow, bolstered by innovation and ongoing R&D efforts.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 612.25 Million |
| Market Size 2030 | USD 954.18 Million |
| CAGR 2025-2030 | 7.68% |
| Fastest Growing Segment | Molecular Diagnostics |
| Largest Market | North America |
Key Market Drivers
Advancements in Sepsis Diagnostic Technologies
Technological innovation has played a central role in transforming sepsis diagnosis, significantly enhancing accuracy and speed. Key advancements include the use of polymerase chain reaction (PCR) for the rapid identification of microbial DNA or RNA, and next-generation sequencing (NGS), which offers comprehensive pathogen detection in a single test. Automated blood culture systems and antibiotic-neutralizing blood culture bottles have improved diagnostic reliability in septic patients undergoing antimicrobial treatment. Additionally, the development of immunoassays for biomarkers such as procalcitonin (PCT) and C-reactive protein (CRP) enables clinicians to assess infection severity and guide treatment decisions. Lateral flow assays now allow point-of-care testing for quicker triage. Host gene expression analysis and emerging microRNA biomarkers also show promise in distinguishing sepsis from other inflammatory conditions. These innovations are enabling faster clinical decision-making, reducing mortality, and expanding the sepsis diagnostics landscape.
Key Market Challenges
Generic Competition
The emergence of generic alternatives in the diagnostic sector presents a significant challenge for established players in the sepsis diagnostics market. Once patent protections expire, generic manufacturers often introduce cost-effective diagnostic solutions that create pricing pressure and reduce profit margins for original manufacturers. This market dynamic forces branded companies to adopt more competitive pricing strategies, potentially affecting their revenue streams. Moreover, the widespread availability of generics can reduce the market share of innovative firms and discourage future investments in R&D, slowing the pace of diagnostic innovation. Ensuring the quality and accuracy of generic diagnostics remains a concern, prompting the need for strict regulatory oversight. Despite offering affordability, generics can disrupt established business models, compelling original manufacturers to differentiate through technological enhancements or value-added services.
Key Market Trends
Biomarker Discovery
Biomarker discovery is rapidly shaping the future of sepsis diagnostics, offering improved precision and speed in identifying and managing the condition. Biomarkers provide specific biological indicators that help differentiate sepsis from other inflammatory or infectious conditions. Their use enables more accurate and earlier diagnoses, which are crucial for timely intervention. Biomarkers such as procalcitonin, CRP, and cytokine profiles are increasingly used to assess infection severity and monitor treatment responses. Additionally, the development of multiplex assays that simultaneously evaluate multiple biomarkers is enhancing diagnostic accuracy. The rise of microRNA profiling and host gene expression analysis is further expanding the biomarker toolkit, allowing for personalized diagnostic approaches. These innovations support the shift toward precision medicine in sepsis care, facilitating targeted and effective treatment strategies. The growing pipeline of biomarker-based tests is expected to fuel market growth by providing clinicians with reliable tools to improve patient outcomes.
Key Market Players
- Abbott Laboratories
- DiaSorin SpA
- Becton, Dickinson, and Company
- BioMerieux Inc.
- F. Hoffmann-La Roche AG
- Danaher Corporation
- Thermo Fisher Scientific Inc
- Siemens Healthineers AG
- Seegene, Inc.
- Roche Diagnostics Corporation
Report Scope:
In this report, the Global Sepsis Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Sepsis Diagnostics Market, By Technology:
- Molecular Diagnostics
- Microbiology
- Immunoassay
- Other Technologies
Sepsis Diagnostics Market, By Product:
- Instruments
- Assays and Reagents
- Other Products
Sepsis Diagnostics Market, By Diagnostic Method:
- Conventional Diagnostics
- Automated Diagnostics
Sepsis Diagnostics Market, By Pathogen:
- Bacterial Sepsis
- Fungal Sepsis
- Other Pathogens
Sepsis Diagnostics Market, By Region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
- Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Sepsis Diagnostics Market.
Available Customizations:
Global Sepsis Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validations
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Sepsis Diagnostics Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Technology (Molecular Diagnostics, Microbiology, Immunoassay, and Other Technologies)
- 5.2.2. By Product (Instruments, Assays and Reagents, and Other Products)
- 5.2.3. By Diagnostic Method (Conventional Diagnostics and Automated Diagnostics)
- 5.2.4. By Pathogen (Bacterial Sepsis, Fungal Sepsis, and Other Pathogens)
- 5.2.5. By Region
- 5.2.6. By Company (2024)
- 5.3. Market Map
6. North America Sepsis Diagnostics Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Technology
- 6.2.2. By Product
- 6.2.3. By Diagnostic Method
- 6.2.4. By Pathogen
- 6.2.5. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Sepsis Diagnostics Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Technology
- 6.3.1.2.2. By Product
- 6.3.1.2.3. By Diagnostic Method
- 6.3.1.2.4. By Pathogen
- 6.3.2. Canada Sepsis Diagnostics Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Technology
- 6.3.2.2.2. By Product
- 6.3.2.2.3. By Diagnostic Method
- 6.3.2.2.4. By Pathogen
- 6.3.3. Mexico Sepsis Diagnostics Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Technology
- 6.3.3.2.2. By Product
- 6.3.3.2.3. By Diagnostic Method
- 6.3.3.2.4. By Pathogen
7. Europe Sepsis Diagnostics Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Technology
- 7.2.2. By Product
- 7.2.3. By Diagnostic Method
- 7.2.4. By Pathogen
- 7.2.5. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Sepsis Diagnostics Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Technology
- 7.3.1.2.2. By Product
- 7.3.1.2.3. By Diagnostic Method
- 7.3.1.2.4. By Pathogen
- 7.3.2. United Kingdom Sepsis Diagnostics Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Technology
- 7.3.2.2.2. By Product
- 7.3.2.2.3. By Diagnostic Method
- 7.3.2.2.4. By Pathogen
- 7.3.3. Italy Sepsis Diagnostics Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Technology
- 7.3.3.2.2. By Product
- 7.3.3.2.3. By Diagnostic Method
- 7.3.3.2.4. By Pathogen
- 7.3.4. France Sepsis Diagnostics Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Technology
- 7.3.4.2.2. By Product
- 7.3.4.2.3. By Diagnostic Method
- 7.3.4.2.4. By Pathogen
- 7.3.5. Spain Sepsis Diagnostics Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Technology
- 7.3.5.2.2. By Product
- 7.3.5.2.3. By Diagnostic Method
- 7.3.5.2.4. By Pathogen
8. Asia-Pacific Sepsis Diagnostics Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Technology
- 8.2.2. By Product
- 8.2.3. By Diagnostic Method
- 8.2.4. By Pathogen
- 8.2.5. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Sepsis Diagnostics Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Technology
- 8.3.1.2.2. By Product
- 8.3.1.2.3. By Diagnostic Method
- 8.3.1.2.4. By Pathogen
- 8.3.2. India Sepsis Diagnostics Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Technology
- 8.3.2.2.2. By Product
- 8.3.2.2.3. By Diagnostic Method
- 8.3.2.2.4. By Pathogen
- 8.3.3. Japan Sepsis Diagnostics Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Technology
- 8.3.3.2.2. By Product
- 8.3.3.2.3. By Diagnostic Method
- 8.3.3.2.4. By Pathogen
- 8.3.4. South Korea Sepsis Diagnostics Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Technology
- 8.3.4.2.2. By Product
- 8.3.4.2.3. By Diagnostic Method
- 8.3.4.2.4. By Pathogen
- 8.3.5. Australia Sepsis Diagnostics Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Technology
- 8.3.5.2.2. By Product
- 8.3.5.2.3. By Diagnostic Method
- 8.3.5.2.4. By Pathogen
9. South America Sepsis Diagnostics Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Technology
- 9.2.2. By Product
- 9.2.3. By Diagnostic Method
- 9.2.4. By Pathogen
- 9.2.5. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Sepsis Diagnostics Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Technology
- 9.3.1.2.2. By Product
- 9.3.1.2.3. By Diagnostic Method
- 9.3.1.2.4. By Pathogen
- 9.3.2. Argentina Sepsis Diagnostics Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Technology
- 9.3.2.2.2. By Product
- 9.3.2.2.3. By Diagnostic Method
- 9.3.2.2.4. By Pathogen
- 9.3.3. Colombia Sepsis Diagnostics Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Technology
- 9.3.3.2.2. By Product
- 9.3.3.2.3. By Diagnostic Method
- 9.3.3.2.4. By Pathogen
10. Middle East and Africa Sepsis Diagnostics Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Technology
- 10.2.2. By Product
- 10.2.3. By Diagnostic Method
- 10.2.4. By Pathogen
- 10.2.5. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Sepsis Diagnostics Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Technology
- 10.3.1.2.2. By Product
- 10.3.1.2.3. By Diagnostic Method
- 10.3.1.2.4. By Pathogen
- 10.3.2. Saudi Arabia Sepsis Diagnostics Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Technology
- 10.3.2.2.2. By Product
- 10.3.2.2.3. By Diagnostic Method
- 10.3.2.2.4. By Pathogen
- 10.3.3. UAE Sepsis Diagnostics Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Technology
- 10.3.3.2.2. By Product
- 10.3.3.2.3. By Diagnostic Method
- 10.3.3.2.4. By Pathogen
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Development
- 12.2. Mergers & Acquisitions
13. Global Sepsis Diagnostics Market: SWOT Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Treatment Types
15. Competitive Landscape
- 15.1. Abbott Laboratories Inc.
- 15.1.1. Business Overview
- 15.1.2. Company Snapshot
- 15.1.3. Products & Services
- 15.1.4. Financials (As Reported)
- 15.1.5. Recent Developments
- 15.1.6. Key Personnel Details
- 15.1.7. SWOT Analysis
- 15.2. DiaSorin SpA
- 15.3. Becton, Dickinson and Company
- 15.4. BioMerieux Inc.
- 15.5. F. Hoffmann-La Roche AG
- 15.6. Danaher Corporation
- 15.7. Thermo Fisher Scientific Inc
- 15.8. Siemens Healthineers AG
- 15.9. Seegene, Inc.
- 15.10. Roche Diagnostics Corporation
16. Strategic Recommendations
17. About Us & Disclaimer
